Adriana Kertzer on Representing the Power of the Plant | The CSE Podcast Ep9-S2

CSE’s Barrington Miller is joined by Adriana Kertzer, Co-Founder of Plant Medicine Law Group, to discuss the unique aspects of representing clients in the cannabis and psychedelics sectors, ongoing policy and regulation issues, and what makes their law firm different from others in this space. The conversation also highlights Adriana’s thoughts on how she sees the plant medicine landscape evolving.

Here’s an overview of what Barrington and Adriana discuss in this edition of the “Exchange for Entrepreneurs” podcast:

0:00 – Introducing Adriana Kertzer and Plant Medicine Law Group
4:13 – Client segments across the psychedelic and cannabis industries
7:43 – A diversity of opinions on plant medicine policy
15:40 – Legality and the psychedelic ecosystem
23:49 – Unique differentiators of Plant Medicine Law Group
28:28 – Going public and being part of a larger community

About Plant Medicine Law Group
Plant Medicine Law Group expands equitable and legal access to plant medicine by helping companies in the psychedelic and cannabis industries thrive in a complex, emerging market. Their strategic expertise empowers clients to successfully launch, fund and scale their business.

Learn more about Plant Medicine Law Group at

Subscribe: Apple Podcasts / Spotify / Stitcher / Google Podcasts / iHeart / RSS

Iris Bincovich on Exporting Ingenuity and the Importance of Milestones | The CSE Podcast Ep8-S2

CSE’s Barrington Miller is joined by Iris Bincovich, CEO of InnoCan Pharma (CSE:INNO) to discuss the company’s focus as a specialty pharmaceutical company including the development of products that harness the unique properties of Cannabinoids combined with smart delivery formulations. The conversation also highlights the importance – and impact – that achieving milestones has had on the company’s life as a public company.

Here’s an overview of what Barrington and Iris discuss in this edition of the “Exchange for Entrepreneurs” podcast:

0:00 – Re-introducing Iris Bincovich and Innocan Pharma
3:31 – Iris’ background in chemistry and the healthcare industry
5:22 – Exporting Israeli innovation across the globe
8:41 – Going public in Canada and the importance of meeting milestones
13:47 – Opportunities for growth in 2022
16:19 – Accessing Innocan’s products
18:35 – Iris’ favourite restaurant

About InnoCan Pharma Corporation
The Corporation’s business can be described as three distinct operating segments relating to the incorporation in products of CBD in their formulation: (i) research, development, marketing, distribution and sales of InnoCan-branded OTC pharmaceutical products; (ii) research and development of non-pharmaceutical products for third parties in exchange for fees and/or royalties; and (iii) research and development of hydrogels containing liposomes intended for licensing or sale to third party pharmaceutical corporations for manufacturing, distribution and sales.

Learn more about InnoCan Pharma at InnoCan Pharma Corporation | CSE – Canadian Securities Exchange (

Subscribe: Apple Podcasts / Spotify / Stitcher / Google Podcasts / iHeart / RSS

Mehran Ehsan on Powering the Future with Oil and Natural Gas | The CSE Podcast Ep7-S2

CSE’s James Black is joined by Mehran Ehsan, CEO of Permex Petroleum (CSE:OIL) to discuss the company’s operations in the Permian Basin in Texas and New Mexico and why Mehran envisions a future where oil and natural gas contribute to world powered by “clean” energy.

Here’s an overview of what James and Mehran discuss in this edition of the “Exchange for Entrepreneurs” podcast:

0:00 – Introducing Mehran Ehsan and Permex Petroleum
0:45 – Why the Oil and Natural Gas Industry?
1:58 – What is impacting gas prices?
3:50 – The impact of Omicron on price
5:50 – What is Permex’s business model?
7:30 – The role of a junior in the Permian Basin
10:20 – Generating royalty interests
11:45 – JP Bryan’s impact on Permex
13:35 – Addressing “dirty oil”

About Permex Petroleum Corporation
Permex Petroleum is a uniquely positioned junior Oil & Gas company with assets and operations across the Permian Basin of west Texas and the Delaware Sub-Basin of south east New Mexico. Permex  has a current focus on identifying, evaluating and acquiring oil and natural gas assets in North America and enhancing and developing its currently held oil and natural gas assets in Texas and New Mexico. Permex owns and operates on Private, State and Federal land.

Learn more about Permex Petroleum at Permex Petroleum Corporation | CSE – Canadian Securities Exchange (

Subscribe: Apple Podcasts / Spotify / Stitcher / Google Podcasts / iHeart / RSS

Anthony Durkacz on Building a Turnaround at FSD Pharma | The CSE Podcast Ep6-S2

CSE’s Barrington Miller is joined by Anthony Durkacz, Interim CEO of FSD Pharma (CSE:HUGE) to discuss the company’s recent history and transition from the cannabis-era to new opportunities in the growing psychedelics space.

Here’s an overview of what Barrington and Anthony discuss in this edition of the “Exchange for Entrepreneurs” podcast:

0:00 – Introducing Anthony Durkacz, Interim CEO of FSD Pharma
5:45 – Working back towards a 1Bn market cap
8:10 – The latest investment in Lucid Psycheceuticals Inc. and treating MS
10:50 – The psychedelics movement
14:13 – Listing on NASDAQ

About FSD Pharma Inc.
FSD Pharma, Inc., is a publicly traded holding company since May 2018.

FSD BioSciences, Inc., a wholly-owned subsidiary, is a specialty biotech pharmaceutical R&D company focused on developing over time multiple applications of its lead compound, FSD201, ultra-micronized palmitoylethanolamide (PEA). Ultra-micro PEA is known to target the CB2 receptors of the endocannabinoid system of the human body and acts by down-regulating the pro-inflammatory cytokines to effectuate an anti-inflammatory response.

The company has successfully completed Phase 1 first-in-human safety and tolerability study for FSD201 and has found the compound to be safe with no serious adverse side effects. This study also validated considerable scientific literature already published in the European Union that claims safety and tolerability of micro-PEA. Ultra-micro PEA is currently beings dispensed in Italy and Spain as a prescription based medical food supplement since 2004.

The company received permission from the Food and Drug Administration (FDA) on June 1, 2020 to submit an Investigational New Drug Application (IND) for the use of FSD201 to treat COVID-19, the disease caused by the SARS-CoV-2 virus.

Severe COVID-19 is characterized by an over-exuberant inflammatory response that may lead to a cytokine storm and ultimately death. The Company is focused on developing FSD201 for its anti-inflammatory properties to avoid the cytokine storm associated with acute lung injury in hospitalized COVID-19 patients.

Learn more about FSD Pharma at FSD Pharma Inc. Subordinate Voting Shares | CSE – Canadian Securities Exchange (

Subscribe: Apple Podcasts / Spotify / Stitcher / Google Podcasts / iHeart / RSS

Jon Matonis on Financing and Banking in the Digital Age | The CSE Podcast Ep5-S2

In Episode 5 of the Exchange for Entrepreneurs Podcast, the CSE’s Anna Serin is joined by Jon Matonis, Chief Economist of Cypherpunk Holdings Inc. (CSE:HODL) to discuss privacy and cryptocurrency, as well as disruptions to financing and banking in the rapidly digitizing economy.

Watch the full interview, or scroll down to read the transcript.

About Cypherpunk Holdings Inc.

Cypherpunk Holdings Inc. is a Canadian-based holding vehicle, set up to invest in technologies and cryptocurrencies with strong privacy.

Learn more about Cypherpunk Holdings Inc. at Cypherpunk Holdings Inc. | CSE – Canadian Securities Exchange (


Anna Serin:

I have the honour of being joined today by Jon Matonis. He is Chief Economist with Cypherpunk Holdings, which is a CSE issuer. But Jon, first of all, thank you so much for joining us today.

Jon Matonis:

No problem, Anna. I’m glad to be here.

Anna Serin:

First of all, I’d love for you to tell us a little bit about your background. You have quite an interesting background. We’re obviously here to have a discussion around finance and banking in digital securities and digital assets, and what’s coming to market. But first of all, why don’t you tell us a little bit about you?

Jon Matonis:

Right. Early on in my career I was the foreign exchange trader for Visa International, going back to the nineties. As the chief foreign exchange dealer for Visa, we covered about $18 billion in international currency trade at that time. Anytime a transaction was made, an exchange rate would hit your statement. That was our team that was putting that exchange rate in.

That gave me a glimpse into the international payment system and how all that worked with various currencies and cards and payment instruments. Which was also about the same time that the world was moving into cryptography, because Visa then became one of the early investors into Verisign. And I moved over from Visa, going into Verisign in the payments division with digital certificates and encryption.

The whole financial cryptography area was booming in the mid to late nineties. And this is all pre Bitcoin, pre cryptocurrency. In fact, the institutions back then were looking at ways to get into the market for being their own currency issuers. You had a group at Visa that was examining how they could be a digital currency issuer by creating a Visa monetary unit, even. They were, in a way, forecasting a lot of the things that we were to see later on.

But it was that blend of finance and cryptography that was so interesting to me, that was booming at the time. And eventually just led me into being involved with digital currencies, going all the way from the mid nineties to when Bitcoin was created in 2008, released in 2009. I wrote extensively on Bitcoin. I wrote for Forbes, I wrote for CoinDesk, and I eventually joined the Bitcoin Foundation as a founding member in 2012.

I was the person behind the Bitcoin conferences that we had in 2013 and 2014. We had the biggest Bitcoin conference in the world at that time in Amsterdam in 2014. The Bitcoin Foundation today is not so much of a driving force in Bitcoin because so many other companies have taken up the task of dedicating money, dedicating developers, and dedicating promotion. But back in the early days, there was nobody that was even forming a narrative for the press. We wanted to fill that vacuum and not let the press deviate into bad press for Bitcoin.

And we were successful in doing that. That takes us to about 2015, 2016, where I, at that point, started working with various companies, as a board director, that were in the crypto space. Focusing on fintech, payments, gaming companies, but also privacy tech and the intersection of privacy tech with finance. Which led me to Cypherpunk Holdings, the current listed company.

The reason that Cypherpunk Holdings and privacy tech is so interesting in this space is that you won’t have any success with cryptocurrencies, or DeFi, or NFTs, or any of those things unless you have a solid foundation of privacy. You’re not going to have any businesses adopt things where payrolls will be public information, or you won’t have any large finance deals happening if the sensitive information is not confidential. There’s a whole entire sub-industry working to solve the privacy problem with these startups. And that’s what Cypherpunk Holdings focuses on.

Anna Serin:

First of all, it’s so interesting to say that you started working with this foundation in 2012. It’s hard to believe that Bitcoin has been around for that long, because I feel like it’s a conversation that people are finally having just within the past maybe two to three years. It’s so interesting that the stuff has been around for so long. And even your work with Visa in the nineties, which might be considered the first digital currencies that were working.

I saw you do an interview and I thought you said something that was really interesting. You said, “Money doesn’t do bad things, bad people do bad things.” And I think that’s a really interesting way to view it. I think people are afraid of privacy around currency, but you did dive into that a little bit. Can you tell us a little bit more about that?

Jon Matonis:

I think you’re right. I think that government and media use the opportunity to tarnish what they want to tarnish. But if you strip it down to its essence, it’s really nothing different than what we already have. The paper cash in your pocket has the same privacy attributes that something like Bitcoin or Ethereum would have.

And mainly those three privacy attributes are: user defined privacy. You get to decide if you reveal information. The second attribute is the irreversibility of the transaction. If you give someone a $100 bill, they have it and you no longer have it. It’s irreversible. And then the third attribute is the non-traceability. You’re not able to link a cash transaction to an individual in all cases as that paper cash moves along the transaction chain.

So when we move to the digital world with something like Bitcoin, it doesn’t add any new, hidden secret privacy techniques. It’s just the same ones that we already had in the analog world with paper cash. Which I don’t think that certain “powers that be” want those same attributes to remain in paper cash, so then they become concerned that those attributes are actually able to be retained when we go digital. This really wasn’t the focus of Visa so much, but it’s a focus of decentralized systems such as Bitcoin on the internet.

Anna Serin:

The original dollar was an IOU, essentially. That’s how paper money was created. We obviously had coins that were made out of certain metals, but the original paper money was IOUs. And now we live in this digital world, so it seems to make sense that we’re entering that side of it.

Can you just tell us a little bit about some of the themes that you’re seeing in finance and banking when it comes to digital securities or digital assets? We can talk about cryptocurrencies, but just in general, what themes are you seeing? What are you seeing come to market in the banking world?

Jon Matonis:

There’s so many new business models that are made possible by this technology, so it ultimately will affect every single area. We’re seeing it go with the low-hanging fruit initially, low-hanging fruit being obviously financial services in the larger sector. But focusing in further within financial services, it’s the early applications around DeFi and decentralized finance, such as lending and earning.

These are normal banking functions, but when you throw it into the world of DeFi, it automatically sometimes takes on this new glamour, because people aren’t used to it without having a physical bank or an old institution. Staking your digital assets refers to earning a yield on your current holdings. It’s just like earning interest that you would earn interest on a CD. You want to earn a yield. There’s many products that are evolving around that. And the entire yield farming market is something that’s new to a lot of people still, but it’s exploding in DeFi land.

Then on the other side of it, you have the lending business. People want to be able to use their collateral for fiat loans. For instance, let’s say that you have a Bitcoin or Ethereum portfolio. You don’t want to liquidate your portfolio, but you want to use it as collateral to get a loan in dollars or euros so that maybe you can make a down payment on a house or something like that.

And there’s a multitude of companies that are springing up to be able to do that and address that market. It’s moving so fast and so quickly that the regulators, not only can they not keep up with it, but they can barely even understand it.

Anna Serin:

Do you think that the financial institutions are resistant to this change?

Jon Matonis:

Largely I do, but I don’t think it’s their fault. I think the financial institutions are resistant to the change because right now they’ve been deputized to be almost a law enforcement wing for financial surveillance. Their agenda is very conflicted.

If you go into any major bank right now and try to discuss anything about new product offerings or the future of finance, what you’ll run into is not open-minded product people, but you’ll run into a wall of attorneys. I mean, the compliance team and the legal teams outnumber the new product teams by a wide margin in banking.

I don’t think it’s their fault because they’ve been deputized in this way and they’ve been chartered, and regulated. But I do think that there’s a certain number of financial institution players that are looking at this space and they’re looking at this space for acquisitions, and that’s how they’ll enter the market.

Anna Serin:

Do you think that we’re going to start seeing this in all of our daily banking? For example, do you think at some point you could go to your brokerage account, deposit Bitcoin, and buy stock?

Jon Matonis:

It’s funny you should say that. I think one of the brokers just announced that they’re accepting cryptocurrency deposits, that was last month. We might start seeing that sooner than you think. But absolutely, the answer is yes, and I think it’s going to be driven by the wallets. And Cypherpunk Holdings has the thesis that it will be driven by the wallets.

Which means just like the browsers steered our entry into the web and how we navigated the web, the digital wallets that people have, whether it’s on their phone or their desktop, it won’t be like a normal wallet. It’ll do so many things for you behind the scenes that you won’t even realize. That user interface is what’s going to allow this technology to go mainstream because it’s going to simplify it for the end user.

For instance, some of the things that you’ll be able to do with your digital wallet, you’ll be able to construct complex smart contracts in DeFi by just plugging your wallet into the web. You’ll be able to have privacy on transactions that you define, which will all be managed by your wallet. The wallets will be able to talk to each other, but everything will still be under your control. Just think of it as we’re moving from browser-based land to wallet-based land to access these services.

Anna Serin:

It’s so interesting. Now my final question for you, and this is a bit of a big one. Hopefully I’m not overwhelming you with an answer. Obviously we know Ethereum and Bitcoin, obviously people can create cryptocurrencies, they have the ability to do so. We also have crypto exchanges that are coming to market where people can trade these.

If we’re implementing this into our everyday banking life with lending, with investing, with financing, how is it being dealt with as far as going back to regular currency exchanges? How are we valuating these cryptocurrencies as they’re coming to market and implementing them into our everyday financial life?

Jon Matonis:

Excellent question. I mean, I’ve never really said that Bitcoin or cryptocurrencies is going to totally eradicate the government fiat currencies. It’s not a situation where you’ll immediately see a replacement like that. I think what you’ll see is Bitcoin keeping the fiat currencies competitive, keeping them honest, so it’ll just be another point of competition for fiat currencies.

And I also don’t think you have to be overwhelmed by 5,000 different cryptocurrencies, because there’s only going to be a handful, maybe two or three, that function as a pure store of value, which would be a currency that people want to hold onto for a store of value to use later. A lot of the other cryptocurrencies are application specific. They give you access to certain smart contract platforms, different blockchains. So we’re not getting into a world of 5,000 different stores of value. There’ll be a small number of competitors.

Think of it like how we settled around Celsius and Fahrenheit and Kelvin for measuring temperature. I mean, we only have three different ways to measure temperature. We’re not going to have a thousand ways to measure value.

Anna Serin:

Super interesting. Jon, everything that you said today I found super interesting. I hope I can bring you back at some point to do another interview.

Definitely take a look at Cypherpunk. I think it stands out a little bit in the market, just the fact that you focus so much on privacy, which is an important element of it. Thank you for your time today and look forward to chatting with you again.

Jon Matonis:

Thanks, Anna.


Subscribe: Apple Podcasts / Spotify / Stitcher / Google Podcasts / iHeart / RSS

Sean Bovingdon on TGOD and Delivering Craft Cannabis at Scale | The CSE Podcast Ep4-S2

CSE’s Barrington Miller is joined by Sean Bovingdon, CEO of The Green Organic Dutchman Holdings Ltd. (CSE:TGOD) to discuss how his company’s expanded focus on the US and recent listing on the Canadian Securities Exchange is setting course for a bright future for the firm.

Here’s an overview of what Barrington and Sean cover in this edition of the “Exchange for Entrepreneurs” podcast:

0:00 – Introducing Sean Bovingdon and TGOD
1:45 – Sean’s past experience in global growth companies
4:30 – The features of organic cannabis
6:54 – Delivering “craft cannabis” at scale
9:20 – Shifting focus to local markets, the US and paying debt
13:53 – Growing revenue and being agile during COVID
16:50 – Prospects for Germany and Mexico
19:00 – What really matters in the cannabis industry

About The Green Organic Dutchman Holdings Ltd.
The Green Organic Dutchman Holdings Ltd. is a premium certified organically grown cannabis company focused on the health and wellness market. Its organic cannabis is cultivated in living soil, as nature intended. The Company is committed to cultivating a better tomorrow by producing its products responsibly, with less waste and impact on the environment. In Canada, TGOD sells dried flower and oil, and recently launched a series of next‐generation cannabis products such as hash, vapes, organic teas and dissolvable powders.

Learn more about The Green Organic Dutchman Holdings Ltd. at The Green Organic Dutchman Holdings Ltd. | CSE – Canadian Securities Exchange (

Subscribe: Apple Podcasts / Spotify / Stitcher / Google Podcasts / iHeart / RSS

Timothy Ko on Treating Addiction with DMT and Psychedelics | The CSE Podcast Ep3-S2

CSE’s Barrington Miller catches up with Timothy Ko, CEO of Entheon Biomedical Corp. (CSE:ENBI) to discuss how his company is pursuing R&D of DMT-based products to safely treat addiction. Timothy provides an update on what the company has accomplished in the year since they’ve been public and upcoming plans for clinical trials.

Here’s an overview of what Barrington and Timothy cover in this edition of the “Exchange for Entrepreneurs” podcast:

0:00 – Catching up with Timothy Ko and Entheon Biomedical
2:30 – What has happened since they listed on the CSE – Canadian Securities Exchange
4:12 – Personalization through genetics
6:20 – The genetics test kit
8:30 – Pathway for clinical trials
9:55 – What’s coming next for investors

About Entheon Biomedical Corp.
Entheon is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective Dimethyltryptamine based psychedelic therapeutic products (“DMT Products”) for the purposes of treating addiction and substance use disorders. Subject to obtaining all requisite regulatory approvals and permits, Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics and licensed psychiatrists in the United States, certain countries in the European Union and throughout Canada.  

Learn more about Entheon Biomedical Corp. at Entheon Biomedical Corp. | CSE – Canadian Securities Exchange (

Subscribe: Apple Podcasts / Spotify / Stitcher / Google Podcasts / iHeart / RSS

Johnson Joseph on Building a “Dating App” for Lending in China | The CSE Podcast Ep2-S2

CSE’s Barrington Miller chats with Johnson Joseph, CEO of Peak Fintech Group Inc. (CSE:PKK) to discuss how his company is building an ecosystem where small and medium businesses (“SMEs”) can easily connect with lending financial institutions to more efficiently access credit.

Here’s an overview of what Barrington and Johnson cover in this edition of the “Exchange for Entrepreneurs” podcast:

0:00 – Introducing Johnson Joseph and Peak Fintech Group
1:13 – Matching small businesses with the right lending opportunities
3:35 – The surprising use-case for their lending platform
5:12 – The technology at the core of Peak’s business
7:28 – The problem that SMEs have accessing credit
8:00 – From “lending hub” to “business hub”
11:38 – Using analytics and AI for lending decision making and ensuring privacy
14:40 – Doing business in China OVER 10 YEARS
19:21 – What’s coming next for investors
21:44 – Dumplings!

About Peak Fintech Group Inc.
Peak Fintech Group Inc. is the parent company of a group of innovative financial technology (Fintech) subsidiaries operating primarily in the commercial lending industry. Peak’s subsidiaries bring together lending financial institutions and businesses to create the Cubeler Business Hub, an ecosystem where analytics and artificial intelligence are used to facilitate transactions among members of the ecosystem.

Learn more about Peak Fintech Group Inc. at Peak Fintech Group Inc. | CSE – Canadian Securities Exchange (

Subscribe: Apple Podcasts / Spotify / Stitcher / Google Podcasts / iHeart / RSS

Ilan Sobel on Unlocking Human Utility Value at BioHarvest Sciences | The CSE Podcast Ep1-S2

CSE’s Barrington Miller chats with Ilan Sobel, CEO of BioHarvest Sciences Inc. (CSE:BHSC) to discuss how his company is combining science & technology with the power of nature to develop breakthrough proprietary and patented Biofarming technologies (plant cell growth).

Here’s an overview of what Barrington and Ilan cover in this edition of the podcast:

0:00 – Introducing Ilan Sobel and BioHarvest Sciences
2:45 – What Ilan learned over 18 years at Coca Cola
6:40 – Developing “Biofarming” technology at BioHarvest
10:20 – Incorporating sustainability into their strategies
13:25 – The intersection of biotech and health and wellness
16:15 – Correlating sustainable technologies and cost
19:55 – Advocating for female leadership in biotechnology
25:00 – Building “human utility value”

About BioHarvest Sciences Inc.
BioHarvest Sciences produces and sells a food-based Nutraceutical product called Vinia™ which contains the whole range of piceid resveratrol in natural state. The product is made by growing plant cells from red grapes in bioreactors utilizing BioHarvest’s platform technology which allows the growing of specific cells instead of the whole plant. BioHarvest Sciences is also completing research to adapt its platform technology to the growing of cannabis cells under a cannabis research license in Israel.

Learn more about BioHarvest Sciences Inc. at

Subscribe: Apple Podcasts / Spotify / Stitcher / Google Podcasts / iHeart / RSS